Noble Drugs Limited - Company Profile

It is a pharma public limited company based in Nashik, Maharashtra, India, established in 1983.
1983 Nashik, Maharashtra, India Active
Last Updated:
Access Report
About Noble Drugs Limited

Noble Drugs Limited, a active public limited company, was established on 21 March 1983 in Nashik, Maharashtra, India. Engaging in drug formulation & development within the pharma sector, it holds CIN: U24100MH1983PLC029592. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹1.00 Cr and a paid-up capital of ₹9.91 M.

Formerly known as Noble Drugs P Limited. It upholds a compliant status. Its leadership includes Shriram Jagannath Dhamne (Director), Vilas Bharat Dhamne (Director), Dnyaneshwar Jagannath Dhamne (Managing Director). It holds no open charges and ₹1.73 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Flat No.4, Ashirwad Apartment Sharanpur Road, Nashik, Maharashtra, 422002.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24100MH1983PLC029592

  • Registration Number

    029592

  • Incorporation Date

    21 March 1983

  • Authorized Capital

    ₹1.00 Cr

  • Paid-Up Capital

    ₹9.91 M

  • ROC Code

    Roc Mumbai

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 1.00 Cr
  • Paid Up Capital ₹ 9.91 M
  • Company Age 42 Year, 11 Months
  • Last Filing with ROC 31 Mar 2024
  • Satisfied Charges ₹ 1.73 Cr
  • Revenue Growth **** 47802.33%
  • Profit Growth **** -1657.10%
  • Ebitda **** -1597.30%
  • Net Worth ****
  • Total Assets **** 2.40%
Company report

Noble Drugs Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Noble Drugs Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Noble Drugs Limited?
Current Directors
Name Designation Appointment Date Status
Shriram Jagannath Dhamne Director 29 Jun 1995 Current
Vilas Bharat Dhamne Director 01 Mar 1996 Current
Dnyaneshwar Jagannath Dhamne Managing Director 20 Nov 1983 Current

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Noble Drugs.

Noble Drugs Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 47802.33% increase. The company also saw a substantial fall in profitability, with a 1657.1% decrease in profit. The company's net worth witnessed no change by increase of 0%.

Noble Drugs revenue growth over time
Noble Drugs profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 47802.33%
*******
*******
*******
*******
Revenue from Operations
*******
 -87.21%
*******
*******
*******
*******
Total Assets
*******
 2.40%
*******
*******
*******
*******
Profit or Loss
*******
 -1657.10%
*******
*******
*******
*******
Net Worth
*******
*******
*******
*******
*******
*******
EBITDA
*******
 -1597.30%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Noble Drugs?

In 2018, Noble Drugs had a promoter holding of 66.70% and a public holding of 33.30%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹0

Satisfied Charges

₹17,349,000.00

Charges Breakdown by Lending Institutions
  • Bank Of India : 1.16 Cr
  • Bamk Of Indai : 0.51 Cr
  • Rchants Co-Op Bnak : 0.04 Cr
  • Maha Rashtra State Financeal Corporation : 0.02 Cr
Latest Charge Details
Date Lender Amount Status
06 Mar 2004 Bank Of India ₹0.67 M Satisfied
23 Jul 2002 Bank Of India ₹1.70 M Satisfied
18 Jun 2002 Bank Of India ₹2.37 M Satisfied
18 Jun 2002 Bank Of India ₹0.50 M Satisfied
18 Jun 2002 Bamk Of Indai ₹0.50 M Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Noble Drugs?

Unlock and access historical data on people associated with Noble Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Noble Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Noble Drugs's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Noble Drugs
Recent Activity within the Organization
  • Annual General Meeting

    The activity Noble Drugs Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.

  • Balance Sheet

    Noble Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai. was recorded as a recent event.

  • Charges

    The activity A charge registered on 17 Jun 1986 via Charge ID 90215074 with Maha Rashtra State Financeal Corporation was fully satisfied on 01 Mar 2012. was completed.

  • Charges

    A charge registered on 06 Mar 2004 via Charge ID 90211124 with Bank Of India was fully satisfied on 14 Nov 2011. was recorded as a recent event.

  • Charges

    A charge registered on 23 Jul 2002 via Charge ID 90213873 with Bank Of India was fully satisfied on 14 Nov 2011. was recorded as a recent event.

  • Charges

    Progress on A charge registered on 18 Jun 2002 via Charge ID 90215761 with Bamk Of Indai was fully satisfied on 14 Nov 2011. was documented.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Noble Drugs Limited?

The CIN of Noble Drugs Limited is U24100MH1983PLC029592.

Where is Noble Drugs Limited headquartered?

Noble Drugs Limited is headquartered at Flat No.4, Ashirwad Apartment Sharanpur Road, Nashik, Maharashtra, 422002.

When was Noble Drugs Limited incorporated?

Noble Drugs Limited was incorporated on 21 March 1983.

Who are the current directors of Noble Drugs Limited?

The current directors of Noble Drugs Limited are

What is the primary industry of Noble Drugs Limited?

The primary industry of Noble Drugs Limited is Pharma.

Is Noble Drugs Limited a listed company?

Noble Drugs Limited is unlisted.

What is the capital structure of Noble Drugs Limited?

The authorized capital of Noble Drugs Limited is ₹1.00 Cr, and the paid-up capital is ₹9.91 M.

What is the compliance status of Noble Drugs Limited?

The compliance status of Noble Drugs Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available